The extension from Nasdaq is a significant positive development for Allarity Therapeutics. It not only provides the company with additional time to meet the necessary compliance requirements but also temporarily alleviates the immediate threat of delisting. This news is likely to be viewed positively by investors, as it reflects confidence from Nasdaq in the company's ability to regain compliance, potentially leading to a short-term positive impact on the stock price.